{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:13:33Z","timestamp":1793754813630,"version":"4.6.1"},"reference-count":313,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>IgG4 subclass antibodies represent the rarest subclass of IgG antibodies, comprising only 3-5% of antibodies circulating in the bloodstream. These antibodies possess unique structural features, notably their ability to undergo a process known as fragment-antigen binding (Fab)-arm exchange, wherein they exchange half-molecules with other IgG4 antibodies. Functionally, IgG4 antibodies primarily block and exert immunomodulatory effects, particularly in the context of IgE isotype-mediated hypersensitivity reactions. In the context of disease, IgG4 antibodies are prominently observed in various autoimmune diseases combined under the term IgG4 autoimmune diseases (IgG4-AID). These diseases include myasthenia gravis (MG) with autoantibodies against muscle-specific tyrosine kinase (MuSK), nodo-paranodopathies with autoantibodies against paranodal and nodal proteins, pemphigus vulgaris and foliaceus with antibodies against desmoglein and encephalitis with antibodies against LGI1\/CASPR2. Additionally, IgG4 antibodies are a prominent feature in the rare entity of IgG4 related disease (IgG4-RD). Intriguingly, both IgG4-AID and IgG4-RD demonstrate a remarkable responsiveness to anti-CD20-mediated B cell depletion therapy (BCDT), suggesting shared underlying immunopathologies. This review aims to provide a comprehensive exploration of B cells, antibody subclasses, and their general properties before examining the distinctive characteristics of IgG4 subclass antibodies in the context of health, IgG4-AID and IgG4-RD. Furthermore, we will examine potential therapeutic strategies for these conditions, with a special focus on leveraging insights gained from anti-CD20-mediated BCDT. Through this analysis, we aim to enhance our understanding of the pathogenesis of IgG4-mediated diseases and identify promising possibilities for targeted therapeutic intervention.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1346671","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:52:25Z","timestamp":1713401545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Exploring the depths of IgG4: insights into autoimmunity and novel treatments"],"prefix":"10.3389","volume":"15","author":[{"given":"Selen","family":"\u00dcnl\u00fc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca G.","family":"S\u00e1nchez Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Cakan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Berchtold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Meleka Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Secil","family":"Vural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atay","family":"Vural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam L.","family":"Fichtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/453843a","article-title":"Translational Research: The full cycle","volume":"453","author":"Ledford","year":"2008","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0923-1811(00)00158-4","article-title":"Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus","volume":"26","author":"Futei","year":"2001","journal-title":"J Dermatol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"Mcconville","year":"2004","journal-title":"Ann Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.01870.x","article-title":"Clinical and experimental features of MuSK antibody positive MG in Japan","volume":"14","author":"Ohta","year":"2007","journal-title":"Eur J Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11144.x","article-title":"Enrichment of total serum IgG4 in patients with pemphigus","volume":"167","author":"Funakoshi","year":"2012","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827689ad","article-title":"Neurofascin as a target for autoantibodies in peripheral neuropathies","volume":"79","author":"Ng","year":"2012","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156800","article-title":"Pathogenicity and epitope characteristics do not differ in igG subclass-switched anti-desmoglein 3 igG1 and igG4 autoantibodies in pemphigus vulgaris","volume":"11","author":"Lo","year":"2016","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01029","article-title":"Autoantibodies against the node of ranvier in seropositive chronic inflammatory demyelinating polyneuropathy: diagnostic, pathogenic, and therapeutic relevance","volume":"9","author":"Vural","year":"2018","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01210-1","article-title":"Autoimmune neurological disorders with igG4 antibodies: a distinct disease spectrum with unique igG4 functions responding to anti-B cell therapies","volume":"19","author":"Dalakas","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.17161\/rrnmf.v4i3","article-title":"The mechanisms of immunopathology underlying B cell depletion therapy-mediated remission and relapse in patients with MuSK MG: Immune mechanisms of MuSK MG","volume":"4","author":"Oconnor","year":"2023","journal-title":"RRNMF Neuromuscular J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B15","author":"Janeway","year":"2017","journal-title":"Immunobiology : the immune system in health and disease; Chapter 8 The Development of B and T Lymphocytes"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.203","article-title":"B cells and antibodies in multiple sclerosis pathogenesis and therapy","volume":"8","author":"Krumbholz","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-074934","article-title":"Immune regulatory function of B cells","volume":"30","author":"Mauri","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nri3857","article-title":"Antibody-independent functions of B cells: a focus on cytokines","volume":"15","author":"Shen","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.06.003","article-title":"New insights into B cells as antigen presenting cells","volume":"70","author":"Ghosh","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T cell development, localization, and function throughout life","volume":"48","author":"Kumar","year":"2018","journal-title":"Immunity"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200208)32:83.0.CO;2-R","article-title":"Availability of antigen-presenting cells can determine the extent of CD4 effector expansion and priming for secretion of Th2 cytokines in vivo","volume":"32","author":"Bradley","year":"2002","journal-title":"Eur J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.05.013","article-title":"Thymic B cells are licensed to present self antigens for central T cell tolerance induction","volume":"42","author":"Yamano","year":"2015","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00319","article-title":"The other function: class II-restricted antigen presentation by B cells","volume":"8","author":"Adler","year":"2017","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.autrev.2011.06.010","article-title":"B-cells and their targeting in rheumatoid arthritis\u2013current concepts and future perspectives","volume":"11","author":"Nakken","year":"2011","journal-title":"Autoimmun Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130699","article-title":"MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies","volume":"210","author":"Molnarfi","year":"2013","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27991","article-title":"Depletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells","volume":"62","author":"B\u00e9land","year":"2015","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.01.018","article-title":"B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production","volume":"33","author":"Jackson","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.10.001","article-title":"B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses","volume":"173","author":"Fraussen","year":"2016","journal-title":"Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nri3802","article-title":"Memory B cells","volume":"15","author":"Kurosaki","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0244-2","article-title":"B cell memory: building two walls of protection against pathogens","volume":"20","author":"Akkaya","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00897-3","article-title":"Memory B cells","volume":"24","author":"Inoue","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/0019-2791(70)90054-6","article-title":"Haptenated bacteriophage in the assay of antibody quantity and affinity: maturation of an immune response","volume":"7","author":"Sarvas","year":"1970","journal-title":"Immunochemistry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/381751a0","article-title":"Clonal selection and learning in the antibody system","volume":"381","author":"Rajewsky","year":"1996","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1042\/bst0300341","article-title":"Novartis Medal Lecture. Antibodies: a paradigm for the evolution of molecular recognition","volume":"30","author":"Neuberger","year":"2002","journal-title":"Biochem Soc Trans"},{"key":"B35","article-title":"Range of normal serum immunoglobulin (IgG, IgA and IgM) values in Nigerians","volume":"13","author":"Oyeyinka","year":"1984","journal-title":"Afr J Med Med Sci"},{"key":"B36","author":"Janeway","year":"2017","journal-title":"Immunobiology : the immune system in health and disease; Chapter 4 Antigen Recognition by B-cell and T-cell Receptors"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jaci.2022.05.023","article-title":"Comprehensive overview of autoantibody isotype and subclass distribution","volume":"150","author":"Volkov","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/2049-632X.12034","article-title":"IgG subclass profiles in normal human sera of antibodies specific to five kinds of microbial antigens","volume":"67","author":"Hjelholt","year":"2013","journal-title":"Pathog Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/antib8020030","article-title":"The ligands for human igG and their effector functions","volume":"8","author":"De Taeye","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-374279-7.05002-5","article-title":"IgG structure and function","volume-title":"Encyclopedia of immunobiology","author":"Thomson","year":"2016"},{"key":"B42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.it.2019.01.005","article-title":"Role of igG3 in infectious diseases","volume":"40","author":"Damelang","year":"2019","journal-title":"Trends Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"Van Der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.20.9036","article-title":"Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1\/IgG2 hybrid and point-mutated antibodies","volume":"88","author":"Chappel","year":"1991","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg7327","article-title":"Is it bad, is it good, or is IgG4 just misunderstood","volume":"8","author":"Pillai","year":"2023","journal-title":"Sci Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1087532","article-title":"Factors affecting IgG4-mediated complement activation","volume":"14","author":"Oskam","year":"2023","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1159\/000233787","article-title":"The role of IgG4 as blocking antibodies in asthmatics and in bee keepers","volume":"77","author":"Nakagawa","year":"1985","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11882-016-0600-2","article-title":"Potential mechanisms for igG4 inhibition of immediate hypersensitivity reactions","volume":"16","author":"James","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00871-z","article-title":"The unique properties of IgG4 and its roles in health and disease","volume":"23","author":"Rispens","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000023918","article-title":"To E or not to E? Can an IL-4-induced B cell choose between IgE and IgG4","volume":"116","author":"Vercelli","year":"1998","journal-title":"Int Arch Allergy Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.136.5.1859","article-title":"IgE responses in human filariasis. IV. Parallel antigen recognition by IgE and IgG4 subclass antibodies","volume":"136","author":"Hussain","year":"1986","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830220816","article-title":"Strong serum inhibition of specific IgE correlated to competing IgG4, revealed by a new methodology in subjects from a S. mansoni endemic area","volume":"22","author":"Rihet","year":"1992","journal-title":"Eur J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.130.2.722","article-title":"Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response","volume":"130","author":"Aalberse","year":"1983","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.137.11.3566","article-title":"Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency","volume":"137","author":"Van Der Zee","year":"1986","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade2798","article-title":"Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination","volume":"8","author":"Irrgang","year":"2023","journal-title":"Sci Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1997.1350806.x","article-title":"The natural history of Apis-specific IgG and IgG4 in beekeepers","volume":"27","author":"Garcia-Robaina","year":"1997","journal-title":"Clin Exp Allergy"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.08.037","article-title":"Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE","volume":"131","author":"Varga","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2017.07.038","article-title":"On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease","volume":"1864","author":"Trampert","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.7.3555","article-title":"IgE versus IgG4 production can be differentially regulated by IL-10","volume":"160","author":"Jeannin","year":"1998","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaci.2022.03.034","article-title":"Distinct disease-specific Tfh cell populations in 2 different fibrotic diseases: IgG(4)-related disease and Kimura disease","volume":"150","author":"Munemura","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2004-829593","article-title":"The epidemiology of myasthenia gravis","volume":"24","author":"Phillips","year":"2004","journal-title":"Semin Neurol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J Med Life"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1159\/000494291","article-title":"Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review and meta-analysis","volume":"52","author":"Broers","year":"2019","journal-title":"Neuroepidemiology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1159351","article-title":"Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid","volume":"14","author":"Rosi-Schumacher","year":"2023","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1069368","article-title":"The diagnosis of anti-LGI1 encephalitis varies with the type of immunodetection assay and sample examined","volume":"13","author":"Mu\u00f1oz-S\u00e1nchez","year":"2022","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223950","article-title":"Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults","volume":"82","author":"Wallace","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-associated myasthenia gravis: clinical features and management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front Neurol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70041-7","article-title":"Chronic inflammatory demyelinating\u00a0polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition","volume":"9","author":"Vallat","year":"2010","journal-title":"Lancet Neurol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","article-title":"Immune-mediated neuropathies","volume":"4","author":"Kieseier","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.10.009","article-title":"Geoepidemiologic considerations of auto-immune pemphigus","volume":"9","author":"Meyer","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B74","article-title":"Pemphigus foliaceus","volume-title":"StatPearls","author":"Lepe","year":"2023"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e01793","DOI":"10.1002\/brb3.1793","article-title":"Anti-LGI1, anti-GABABR, and Anti-CASPR2 encephalitides in Asia: A systematic review","volume":"10","author":"Ghimire","year":"2020","journal-title":"Brain Behav"},{"key":"B76","doi-asserted-by":"publisher","first-page":"17562864211073203","DOI":"10.1177\/17562864211073203","article-title":"Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1\/Caspr2 encephalitis: a prospective cohort study in Western China","volume":"15","author":"Guo","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.114868","article-title":"Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy","volume":"78","author":"Chi\u00f2","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21206","article-title":"Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population","volume":"39","author":"Rajabally","year":"2009","journal-title":"Muscle Nerve"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1159\/000445884","article-title":"Incidence and natural history of idiopathic chronic inflammatory demyelinating polyneuropathy: A population-based study in Iceland","volume":"75","author":"Hafsteinsdottir","year":"2016","journal-title":"Eur Neurol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.xjidi.2021.100004","article-title":"Epidemiology of pemphigus","volume":"1","author":"Kridin","year":"2021","journal-title":"JID Innov"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315720","article-title":"LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes","volume":"89","author":"Binks","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000218159.79769.5c","article-title":"Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5","volume":"66","author":"Niks","year":"2006","journal-title":"Neurology"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000339103.08830.86","article-title":"HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5","volume":"72","author":"Bartoccioni","year":"2009","journal-title":"Neurology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.08.271","article-title":"Association of HLA-DRB1\u221714, -DRB1\u221716 and -DQB1\u221705 with MuSK-myasthenia gravis in patients from Turkey","volume":"74","author":"Alahgholi-Hajibehzad","year":"2013","journal-title":"Hum Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.11.021","article-title":"Association of HLA class II (DRB1, DQA1, DQB1) alleles and haplotypes with myasthenia gravis and its subgroups in the Iranian population","volume":"359","author":"Ehsan","year":"2015","journal-title":"J Neurol Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.12525","article-title":"High frequency of DQB1*05 and absolute absence of DRB1*13 in muscle-specific tyrosine kinase positive myasthenia gravis","volume":"22","author":"Nikolic","year":"2015","journal-title":"Eur J Neurol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.02.031","article-title":"HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients","volume":"363","author":"Kanai","year":"2016","journal-title":"J Neurol Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/ane.2018.138.issue-3","article-title":"HLA and MuSK-positive myasthenia gravis: A systemic review and meta-analysis","volume":"138","author":"Hong","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"B90","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/jns5.12074","article-title":"Genetics of Guillain-Barr\u00e9 syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions","volume":"19","author":"Blum","year":"2014","journal-title":"J Peripher Nerv Syst"},{"key":"B91","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1399-0039.1997.tb02707.x","article-title":"An epitope in the third hypervariable region of the DRB1 gene is involved in the susceptibility to endemic pemphigus foliaceus (fogo selvagem) in three different Brazilian populations","volume":"49","author":"Moraes","year":"1997","journal-title":"Tissue Antigens"},{"key":"B92","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1006\/jaut.2000.0388","article-title":"HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus","volume":"15","author":"Loiseau","year":"2000","journal-title":"J Autoimmun"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00226","article-title":"The genetics of pemphigus vulgaris","volume":"5","author":"Vodo","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1590\/1678-4685-gmb-2019-0369","article-title":"Beyond the HLA polymorphism: A complex pattern of genetic susceptibility to pemphigus","volume":"43","author":"Petzl-Erler","year":"2020","journal-title":"Genet Mol Biol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24860","article-title":"Anti-LGI1 encephalitis is associated with unique HLA subtypes","volume":"81","author":"Kim","year":"2017","journal-title":"Ann Neurol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy109","article-title":"Distinct HLA associations of LGI1 and CASPR2-antibody diseases","volume":"141","author":"Binks","year":"2018","journal-title":"Brain"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323226","article-title":"Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features","volume":"91","author":"Mu\u00f1iz-Castrillo","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30006-2","article-title":"IgG4-related disease in the Japanese population: a genome-wide association study","volume":"1","author":"Terao","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81252-0","article-title":"Agrin acts via a MuSK receptor complex","volume":"85","author":"Glass","year":"1996","journal-title":"Cell"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1084\/jem.144.3.739","article-title":"Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies","volume":"144","author":"Lindstrom","year":"1976","journal-title":"J Exp Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PloS One"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200147","article-title":"IgG1-3 muSK antibodies inhibit AChR cluster formation, restored by SHP2 inhibitor, despite normal muSK, DOK7, or AChR subunit phosphorylation","volume":"10","author":"Cao","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000547","article-title":"MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity","volume":"6","author":"Huijbers","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127167","article-title":"Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients","volume":"4","author":"Takata","year":"2019","journal-title":"JCI Insight"},{"key":"B114","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s40478-022-01454-0","article-title":"Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy","volume":"10","author":"Fichtner","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.7.2895","article-title":"Muscle-specific trk-related receptor with a kringle domain defines a distinct class of receptor tyrosine kinases","volume":"90","author":"Jennings","year":"1993","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B116","doi-asserted-by":"publisher","first-page":"13928","DOI":"10.1038\/srep13928","article-title":"Collagen Q and anti-MuSK autoantibody competitively suppress agrin\/LRP4\/MuSK signaling","volume":"5","author":"Otsuka","year":"2015","journal-title":"Sci Rep"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann Neurol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06808.x","article-title":"Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis","volume":"1275","author":"Plomp","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200513","article-title":"Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis","volume":"217","author":"Fichtner","year":"2020","journal-title":"J Exp Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020635118","article-title":"Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis","volume":"118","author":"Vergoossen","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long lasting rituximab-induced reduction of specific - but not of total- IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/pnp.738","article-title":"Changes in antibody titers and clinical course in myasthenia gravis retrospective study","volume":"26","author":"Berger","year":"2022","journal-title":"Prog Neurol Psychiatry"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26609","article-title":"Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: A marker of relapse","volume":"60","author":"Triplett","year":"2019","journal-title":"Muscle Nerve"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.03.026","article-title":"History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"93","author":"Dyck","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27046","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach","volume":"63","author":"Stino","year":"2021","journal-title":"Muscle Nerve"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.260","article-title":"Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders","volume":"11","author":"Stathopoulos","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317192","article-title":"Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground","volume":"89","author":"Uncini","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.4103\/aian.aian_382_22","article-title":"Nodo-paranodopathies: concepts, clinical implications, and management","volume":"25","author":"Khadilkar","year":"2022","journal-title":"Ann Indian Acad Neurol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1111\/jns.12569","article-title":"Autoimmune nodo-paranodopathies 10\u2009years later: Clinical features, pathophysiology and treatment","author":"Uncini","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071053","article-title":"Neurofascin as a novel target for autoantibody-mediated axonal injury","volume":"204","author":"Mathey","year":"2007","journal-title":"J Exp Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23794","article-title":"Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy","volume":"73","author":"Querol","year":"2012","journal-title":"Ann Neurol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww189","article-title":"Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy","volume":"139","author":"Doppler","year":"2016","journal-title":"Brain"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx124","article-title":"Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy","volume":"140","author":"Delmont","year":"2017","journal-title":"Brain"},{"key":"B138","doi-asserted-by":"publisher","first-page":"14411","DOI":"10.1038\/s41598-017-14853-4","article-title":"Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"7","author":"Querol","year":"2017","journal-title":"Sci Rep"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww062","article-title":"Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects","volume":"139","author":"Manso","year":"2016","journal-title":"Brain"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124694","article-title":"Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo","volume":"129","author":"Manso","year":"2019","journal-title":"J Clin Invest"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200014","article-title":"IgG4 valency modulates the pathogenicity of anti\u2013neurofascin-155 igG4 in autoimmune nodopathy","volume":"9","author":"Jentzer","year":"2022","journal-title":"Neurol - Neuroimmunology Neuroinflamm"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1021513","article-title":"Effect of monovalency on anti-contactin-1 IgG4","volume":"14","author":"Taieb","year":"2023","journal-title":"Front Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac418","article-title":"Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage","volume":"146","author":"Appeltshauser","year":"2023","journal-title":"Brain"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12565","article-title":"Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response","volume":"28","author":"Bresciani","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/medicina57101080","article-title":"An updated review of pemphigus diseases","volume":"57","author":"Malik","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2022.02.023","article-title":"Desmoglein 2 can undergo Ca2+-dependent interactions with both desmosomal and classical cadherins including E-cadherin and N-cadherin","volume":"121","author":"Fuchs","year":"2022","journal-title":"Biophys J"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.86.524","article-title":"Autoimmune and infectious skin diseases that target desmogleins","volume":"86","author":"Amagai","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64413","article-title":"Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface","volume":"122","author":"Di Zenzo","year":"2012","journal-title":"J Clin Invest"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198906013202206","article-title":"The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem)","volume":"320","author":"Rock","year":"1989","journal-title":"N Engl J Med"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23714.x","article-title":"In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in pemphigus vulgaris","volume":"124","author":"Ishii","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24185","article-title":"Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display","volume":"115","author":"Payne","year":"2005","journal-title":"J Clin Invest"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050696","article-title":"Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation","volume":"7","author":"Saito","year":"2012","journal-title":"PloS One"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.11.5239","article-title":"Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity","volume":"92","author":"Bhol","year":"1995","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03659.x","article-title":"The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives","volume":"143","author":"Kricheli","year":"2000","journal-title":"Br J Dermatol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12017.x","article-title":"The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus","volume":"120","author":"Warren","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M607963200","article-title":"Anti-desmoglein 3 (Dsg3) monoclonal antibodies deplete desmosomes of Dsg3 and differ in their Dsg3-depleting activities related to pathogenicity","volume":"282","author":"Yamamoto","year":"2007","journal-title":"J Biol Chem"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15721","article-title":"Inhibition of p38MAPK signalling prevents epidermal blistering and alterations of desmosome structure induced by pemphigus autoantibodies in human epidermis","volume":"177","author":"Egu","year":"2017","journal-title":"Br J Dermatol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jdermsci.2016.12.010","article-title":"Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering","volume":"85","author":"Yoshida","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114426","article-title":"Monovalent Fab\u2019 immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb\/c mice","volume":"85","author":"Rock","year":"1990","journal-title":"J Clin Invest"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1997.4408","article-title":"Mechanisms of acantholysis in pemphigus vulgaris: role of IgG valence","volume":"85","author":"Mascar\u00f3","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ajpath.2011.04.015","article-title":"Pathogenic relevance of IgG and IgM antibodies against desmoglein 3 in blister formation in pemphigus vulgaris","volume":"179","author":"Tsunoda","year":"2011","journal-title":"Am J Pathol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1468-3083.1998.tb00924.x","article-title":"Use of recombinant pemphigus vulgaris antigen in development of ELISA and IB assays to detect pemphigus vulgaris autoantibodies","volume":"10","author":"Bhol","year":"1998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2012.1901","article-title":"Evaluation of commercially available ELISA assays as a tool for monitoring and managing pemphigus patients: a prospective study","volume":"23","author":"Bracke","year":"2013","journal-title":"Eur J Dermatol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cells13010015","article-title":"Pathophysiological effects of autoantibodies in autoimmune encephalitides","volume":"13","author":"Ryding","year":"2024","journal-title":"Cells"},{"key":"B165","doi-asserted-by":"publisher","first-page":"103074","DOI":"10.1016\/j.autrev.2022.103074","article-title":"Contemporary advances in antibody-mediated encephalitis: anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides","volume":"21","author":"Seery","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B166","doi-asserted-by":"publisher","first-page":"18161","DOI":"10.1523\/JNEUROSCI.3506-13.2013","article-title":"Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors","volume":"33","author":"Toshika","year":"2013","journal-title":"J Neurosci"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy253","article-title":"LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory","volume":"141","author":"Petit-Pedrol","year":"2018","journal-title":"Brain"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26345","article-title":"Human CASPR2 antibodies reversibly alter memory and the CASPR2 protein complex","volume":"91","author":"Joubert","year":"2022","journal-title":"Ann Neurol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ana.25120","article-title":"Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia","volume":"83","author":"Patterson","year":"2018","journal-title":"Ann Neurol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0500-7","article-title":"IgG4-related disease: an update on pathophysiology and implications for clinical care","volume":"16","author":"Perugino","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-003-1175-y","article-title":"A new clinicopathological entity of IgG4-related autoimmune disease","volume":"38","author":"Kamisawa","year":"2003","journal-title":"J Gastroenterol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1104650","article-title":"IgG4-related disease","volume":"366","author":"Stone","year":"2012","journal-title":"New Engl J Med"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.41120","article-title":"The 2019 american college of rheumatology\/european league against rheumatism classification criteria for igG4-related disease","volume":"72","author":"Wallace","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/08916934.2017.1280029","article-title":"Clonally expanded cytotoxic CD4+ T cells and the pathogenesis of IgG4-related disease","volume":"50","author":"Mattoo","year":"2017","journal-title":"Autoimmunity"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000686","article-title":"Immune mechanisms of fibrosis and inflammation in IgG4-related disease","volume":"32","author":"Pillai","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.022","article-title":"CD4(+) and CD8(+) cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG(4)-related disease","volume":"147","author":"Perugino","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaci.2018.05.01","article-title":"Identification of galectin-3 as an autoantigen in patients with IgG(4)-related disease","volume":"143","author":"Perugino","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1595-3","article-title":"Analysis of the B cell receptor repertoire in six immune-mediated diseases","volume":"574","author":"Bashford-Rogers","year":"2019","journal-title":"Nature"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis","volume":"82","author":"Blum","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis","volume":"74","author":"Robeson","year":"2016","journal-title":"JAMA Neurol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128269","article-title":"Expansion of activated peripheral blood memory B cells in rheumatoid arthritis, impact of B cell depletion therapy, and biomarkers of response","volume":"10","author":"Adlowitz","year":"2015","journal-title":"PloS One"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136471","article-title":"Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses","volume":"5","author":"Jiang","year":"2020","journal-title":"JCI Insight"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000149","article-title":"Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins","volume":"2","author":"Querol","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12287","article-title":"Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases","volume":"23","author":"Roux","year":"2018","journal-title":"J Peripheral Nervous Syst"},{"key":"B193","doi-asserted-by":"publisher","first-page":"577280","DOI":"10.1016\/j.jneuroim.2020.577280","article-title":"Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155","volume":"345","author":"Jiao","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001098","article-title":"Clinical and laboratory features in anti-NF155 autoimmune nodopathy","volume":"9","author":"Mart\u00edn-Aguilar","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B195","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/acn3.51550","article-title":"Clinical and diagnostic features of anti-neurofascin-155 antibody-positive neuropathy in Han Chinese","volume":"9","author":"Wang","year":"2022","journal-title":"Ann Clin Trans Neurol"},{"key":"B196","first-page":"379","article-title":"Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells","volume":"144","author":"Leuci","year":"2009","journal-title":"G Ital Dermatol Venereol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14633","article-title":"Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration","volume":"34","author":"Mahmoudi","year":"2021","journal-title":"Dermatologic Ther"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE registry","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19416","article-title":"Rituximab in the management of refractory myasthenia gravis and variability of its efficacy in anti-muSK positive and anti-AChR positive myasthenia gravis","volume":"13","author":"Bastakoti","year":"2021","journal-title":"Cureus"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.05.013","article-title":"Rituximab in chronic immune mediated neuropathies: a systematic review","volume":"32","author":"Chaganti","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180300","article-title":"Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.02.037","article-title":"Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases","volume":"71","author":"Mahmoudi","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121705","article-title":"Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody","volume":"14","author":"Bai","year":"2023","journal-title":"Front Immunol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14498","article-title":"Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies","volume":"27","author":"Casertano","year":"2020","journal-title":"Eur J Neurol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600089","article-title":"Features of human CD3+CD20+ T cells","volume":"197","author":"Schuh","year":"2016","journal-title":"J Immunol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"20499","DOI":"10.1038\/s41598-021-00007-0","article-title":"CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties","volume":"11","author":"Vlaming","year":"2021","journal-title":"Sci Rep"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-022-01622-x","article-title":"CD20(+) T cells: an emerging T cell subset in human pathology","volume":"71","author":"Lee","year":"2022","journal-title":"Inflammation Res"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J Immunol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/cyto.990140212","article-title":"CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes","volume":"14","author":"Hultin","year":"1993","journal-title":"Cytometry"},{"key":"B213","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/art.27527","article-title":"CD3+CD20+ cells may be an artifact of flow cytometry: comment on the article by Wilk et\u00a0al","volume":"62","author":"Henry","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1002\/art.24998","article-title":"Depletion of functionally active CD20+ T cells by rituximab treatment","volume":"60","author":"Wilk","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.999536","article-title":"CD20(+) T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer","volume":"4","author":"De Bruyn","year":"2015","journal-title":"Oncoimmunology"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2019.01.001","article-title":"CD3(+)CD20(+) T cells and their roles in human diseases","volume":"80","author":"Chen","year":"2019","journal-title":"Hum Immunol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi4632","article-title":"Proinflammatory CD20(+) T cells contribute to CNS-directed autoimmunity","volume":"14","author":"Ochs","year":"2022","journal-title":"Sci Transl Med"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.1996.tb01096.x","article-title":"Transient expression of CD20 antigen (pan B cell marker) in activated lymph node T cells","volume":"40","author":"Murayama","year":"1996","journal-title":"Microbiol Immunol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00884.x","article-title":"CD20-positive T-cell chronic lymphocytic leukaemia","volume":"102","author":"Takami","year":"1998","journal-title":"Br J Haematol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1915309116","article-title":"Anti-CD20 therapy depletes activated myelin-specific CD8(+) T cells in multiple sclerosis","volume":"116","author":"Sabatino","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200084","article-title":"Ocrelizumab impairs the phenotype and function of memory CD8(+) T cells: A 1-year longitudinal study in patients with multiple sclerosis","volume":"10","author":"Mathias","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207291120","article-title":"Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity","volume":"120","author":"Shinoda","year":"2023","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B224","doi-asserted-by":"publisher","first-page":"R51","DOI":"10.1186\/ar4481","article-title":"Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sj\u00f6gren\u2019s syndrome","volume":"16","author":"Hershberg","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aan8289","article-title":"Dynamics of the human antibody repertoire after B cell depletion in systemic sclerosis","volume":"2","author":"De Bourcy","year":"2017","journal-title":"Sci Immunol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheumatism"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-123844","article-title":"The human spleen is a major reservoir for long-lived vaccinia virus\u2013specific memory B cells","volume":"111","author":"Mamani-Matsuda","year":"2008","journal-title":"Blood"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology"},{"key":"B229","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B230","doi-asserted-by":"publisher","first-page":"175ra130","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"B231","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jneuroim.2015.11.006","article-title":"Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination","volume":"290","author":"Maurer","year":"2016","journal-title":"J Neuroimmunol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13024","article-title":"B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets","volume":"190","author":"Becerra","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B233","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"B234","doi-asserted-by":"publisher","first-page":"1756286418761697","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1002\/art.38334","article-title":"Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc\u03b3 receptor IIb inhibitory receptor","volume":"66","author":"Chu","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515620934","article-title":"Placebo-controlled study in neuromyelitis optica-Ethical and design considerations","volume":"22","author":"Cree","year":"2016","journal-title":"Mult Scler"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.2119\/2006-00086.Lee","article-title":"Structure and enzymatic functions of human CD38","volume":"12","author":"Lee","year":"2006","journal-title":"Mol Med"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"key":"B240","doi-asserted-by":"publisher","first-page":"103289","DOI":"10.1016\/j.autrev.2023.103289","article-title":"The potential of CD38 protein as a target for autoimmune diseases","volume":"22","author":"Ye","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6619","article-title":"Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma","volume":"12","author":"Bisht","year":"2023","journal-title":"Cancer Med"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04917-5","article-title":"Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes","volume":"101","author":"Leleu","year":"2022","journal-title":"Ann Hematol"},{"key":"B243","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv Drug Delivery Rev"},{"key":"B244","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B245","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jocn.2023.11.013","article-title":"Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study","volume":"119","author":"Gomezmancilla","year":"2024","journal-title":"J Clin Neurosci"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B247","doi-asserted-by":"publisher","first-page":"dgz013","DOI":"10.1210\/clinem\/dgz013","article-title":"A novel anti-CD40 monoclonal antibody, iscalimab, for control of graves hyperthyroidism-A proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700016","article-title":"Tolerance induction by the blockade of CD40\/CD154 interaction in pemphigus vulgaris mouse model","volume":"126","author":"Aoki-Ota","year":"2006","journal-title":"J Invest Dermatol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2019.01.001","article-title":"Pharmacological advances in pemphigus","volume":"46","author":"Bilgic Temel","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"B250","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-60327-013-7","volume-title":"BLyS ligands and receptors","author":"Cancro","year":"2010"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.05.010","article-title":"Serum BAFF expression in patients with myasthenia gravis","volume":"199","author":"Kim","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000077","article-title":"Characterization of B cells in muscle-specific kinase antibody myasthenia gravis","volume":"2","author":"Guptill","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25162","article-title":"B-cell-activating factor is elevated in serum of patients with myasthenia gravis","volume":"54","author":"Kang","year":"2016","journal-title":"Muscle Nerve"},{"key":"B255","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int Rev Immunol"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14483","article-title":"Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma","volume":"176","author":"Raje","year":"2017","journal-title":"Br J Haematol"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"B261","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","article-title":"TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS","volume":"15","author":"Gross","year":"2001","journal-title":"Immunity"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial","volume":"56","author":"Dall\u2019era","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B263","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.23178","article-title":"Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study","volume":"58","author":"Tak","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT","article-title":"Profile of atacicept and its potential in the treatment of systemic lupus erythematosus","volume":"9","author":"Cogollo","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1291343","article-title":"Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)","volume":"13","author":"Stohl","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","author":"Di","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-009-2838-6","article-title":"[Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis]","volume":"80","author":"Hartung","year":"2009","journal-title":"Nervenarzt"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1177\/1756285610371146","article-title":"Atacicept: targeting B cells in multiple sclerosis","volume":"3","author":"Hartung","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"B271","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/TCRM.S252592","article-title":"Emerging B-cell therapies in systemic lupus erythematosus","volume":"17","author":"Bag-Ozbek","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111595","article-title":"Proteasome inhibitors and their pharmacokinetics, pharmacodynamics, and metabolism","volume":"22","author":"Wang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.952304","article-title":"B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools","volume":"9","author":"Parodis","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201847492","article-title":"Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors","volume":"48","author":"Alexander","year":"2018","journal-title":"Eur J Immunol"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.08.005","article-title":"ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response","volume":"311","author":"Liu","year":"2017","journal-title":"J Neuroimmunology"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301555","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients","volume":"193","author":"Gomez","year":"2014","journal-title":"J Immunol"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830260718","article-title":"An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta","volume":"26","author":"Simister","year":"1996","journal-title":"Eur J Immunol"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1038\/372336a0","article-title":"Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor","volume":"372","author":"Burmeister","year":"1994","journal-title":"Nature"},{"key":"B282","doi-asserted-by":"publisher","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.4520","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B284","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jid.2021.04.031","article-title":"Safety, tolerability, and activity of ALXN1830 targeting the neonatal fc receptor in chronic pemphigus","volume":"141","author":"Werth","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13663","article-title":"Complement: Functions, location and implications","volume":"170","author":"Kareem","year":"2023","journal-title":"Immunology"},{"key":"B287","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"Rodgaard","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11617-1","article-title":"Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"270","author":"Vu","year":"2023","journal-title":"J Neurol"},{"key":"B290","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1111\/all.15261","article-title":"Bruton\u2019s tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions","volume":"77","author":"Mendes-Bastos","year":"2022","journal-title":"Allergy"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton\u2019s tyrosine kinase in the immune system and disease","volume":"164","author":"Mcdonald","year":"2021","journal-title":"Immunology"},{"key":"B293","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1615\/CritRevImmunol.v38.i1","article-title":"The role of bruton\u2019s tyrosine kinase in immune cell signaling and systemic autoimmunity","volume":"38","author":"Rip","year":"2018","journal-title":"Crit Rev Immunol"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B295","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"key":"B296","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B299","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002907","article-title":"CAR T cells for treating autoimmune diseases","volume":"9","author":"Blache","year":"2023","journal-title":"RMD Open"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"B307","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.56.7.481","article-title":"Pathogenesis of systemic lupus erythematosus","volume":"56","author":"Mok","year":"2003","journal-title":"J Clin Pathol"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Res"},{"key":"B312","doi-asserted-by":"publisher","first-page":"R38","DOI":"10.1530\/EC-17-0347","article-title":"On type 1 diabetes mellitus pathogenesis","volume":"7","author":"Paschou","year":"2018","journal-title":"Endocr Connect"},{"key":"B313","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1346671\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:52:31Z","timestamp":1713401551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1346671\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":313,"alternative-id":["10.3389\/fimmu.2024.1346671"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1346671","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"article-number":"1346671"}}